IBM's earnings problem goes beyond a slowdown in China
07/18/2013 6:29 pm EST
After the close of New York markets on July 17, IBM (IBM) reported second quarter earnings of $3.91 per share (excluding a $1 billion charge for “rebalancing” its workforce that Wall Street called a non-recurring item even though this has become business as usual at IBM.) That was above the $3.78 a share projected by Wall Street. Revenue fell by 3.3% year over year to $24.92 billion, below the $25.3 billion analysts had projected.
A big part of the revenue problem for the quarter was that IBM’s growth markets in the emerging economies didn’t show much growth. Revenue from the BRIC countries was flat year over year (or up 1% in constant currencies.) That certainly didn’t make up for the 3% decline in North American revenue or flat revenue from the company’s Europe/Middle Eat/Africa sales region.
The quarter illustrates that IBM has an ongoing problem with earnings growth. IBM continues to generate hefty cash flows—$16.95 a share in 2012—but with revenue showing very little growth, much of the company’s earnings growth is coming from cost cutting (that workforce “rebalancing) and share repurchases. Credit Suisse calculates that cost cutting, improvements in product mix that increase margins, and share purchases have accounted for 50% of growth in earnings per share in recent quarters.
IBM did raise its forecast for 2013 non-GAAP earnings per share to $16.86 for 2013 from $16.55. But I think investors would be advised to focus on the recent quality of IBM’s earnings and earnings growth and ask what multiple they want to pay for the company’s growth. The stock currently trades at 13.2 times trailing 12-month earnings. Standard & Poor’s calculates a 12-month target price for these shares of $227. That would be a 14.5% gain from the 2:30 p.m. New York time price on July 18 of $198.17.
I would note, however, that S&P gets to that price by assuming that the multiple that investors will pay for IBM’s earnings and growth will increase to 13.6 from the current 13.2.
I find that assumption questionable unless you’re willing to assume that the multiple for the entire U.S. market continues to climb over the next twelve months on a belief in faster economic and earnings growth.
Full disclosure: I don’t own shares of any of the companies mentioned in this post in my personal portfolio. When in 2010 I started the mutual fund I manage, Jubak Global Equity Fund http://jubakfund.com/ , I liquidated all my individual stock holdings and put the money into the fund. The fund did not own shares of any stock mentioned in this post as of the end of March. For a full list of the stocks in the fund as of the end of March see the fund’s portfolio at http://jubakfund.com/about-the-fund/holdings/
Related Articles on STOCKS
We hold three biotech stocks in our growth portfolio — Biogen (BIIB), Bioverativ (BIVV), and R...
Under the guise of clamping down on “widespread corruption,” Prince Mohammed bin Salman ...
Leading value investor and money manager John Buckingham sees upside potential in two banking stocks...